[1]
Gözdaşoğlu S. Kasabach-Merritt Syndrome in an Adult: A Comment. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2019 Feb 7:36(1):52-53. doi: 10.4274/tjh.galenos.2018.2018.0356. Epub 2018 Oct 22
[PubMed PMID: 30345972]
Level 3 (low-level) evidence
[2]
Ji Y, Chen S, Li L, Yang K, Xia C, Li L, Yang G, Kong F, Lu G, Liu X. Kaposiform hemangioendothelioma without cutaneous involvement. Journal of cancer research and clinical oncology. 2018 Dec:144(12):2475-2484. doi: 10.1007/s00432-018-2759-5. Epub 2018 Oct 6
[PubMed PMID: 30293120]
[3]
Ji Y, Chen S, Yang K, Xia C, Peng S. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence? The Journal of dermatology. 2018 Oct:45(10):1203-1206. doi: 10.1111/1346-8138.14598. Epub 2018 Aug 17
[PubMed PMID: 30118141]
[4]
Schmid I, Klenk AK, Sparber-Sauer M, Koscielniak E, Maxwell R, Häberle B. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options. World journal of pediatrics : WJP. 2018 Aug:14(4):322-329. doi: 10.1007/s12519-018-0171-5. Epub 2018 Jul 27
[PubMed PMID: 30054848]
[5]
Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt Phenomenon: Classic Presentation and Management Options. Clinical medicine insights. Blood disorders. 2017:10():1179545X17699849. doi: 10.1177/1179545X17699849. Epub 2017 Mar 16
[PubMed PMID: 28579853]
[6]
Gültekin ND, Yilmaz FH, Altunhan H, Findik S, Tokgöz H, Çalişkan Ü. Coexistence of Kasabach-Merritt Syndrome and placental chorioangioma in a premature infant. Journal of neonatal-perinatal medicine. 2018:11(2):209-213. doi: 10.3233/NPM-181754. Epub
[PubMed PMID: 29991142]
[7]
Shimizu Y, Komura T, Seike T, Omura H, Kumai T, Kagaya T, Ohta H, Kawashima A, Harada K, Kaneko S, Unoura M. A case of an elderly female with diffuse hepatic hemangiomatosis complicated with multiple organic dysfunction and Kasabach-Merritt syndrome. Clinical journal of gastroenterology. 2018 Oct:11(5):411-416. doi: 10.1007/s12328-018-0871-3. Epub 2018 May 29
[PubMed PMID: 29845554]
Level 3 (low-level) evidence
[8]
Erdem Toslak I, Stegman M, Reiter MP, Barkan GA, Borys D, Lim-Dunham JE. Atypically presenting kaposiform hemangioendothelioma of the knee: ultrasound findings. Journal of medical ultrasonics (2001). 2018 Oct:45(4):653-656. doi: 10.1007/s10396-018-0878-x. Epub 2018 Apr 10
[PubMed PMID: 29637402]
[9]
Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC 3rd. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. The Journal of pediatrics. 2013 Jan:162(1):142-7. doi: 10.1016/j.jpeds.2012.06.044. Epub 2012 Aug 4
[PubMed PMID: 22871490]
[10]
Putra J, Gupta A. Kaposiform haemangioendothelioma: a review with emphasis on histological differential diagnosis. Pathology. 2017 Jun:49(4):356-362. doi: 10.1016/j.pathol.2017.03.001. Epub 2017 Apr 21
[PubMed PMID: 28438388]
[11]
Kelly M. Kasabach-Merritt phenomenon. Pediatric clinics of North America. 2010 Oct:57(5):1085-9. doi: 10.1016/j.pcl.2010.07.006. Epub 2010 Aug 21
[PubMed PMID: 20888459]
[12]
O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. British journal of haematology. 2015 Oct:171(1):38-51. doi: 10.1111/bjh.13557. Epub 2015 Jun 30
[PubMed PMID: 26123689]
Level 3 (low-level) evidence
[13]
Ryan C, Price V, John P, Mahant S, Baruchel S, Brandão L, Blanchette V, Pope E, Weinstein M. Kasabach-Merritt phenomenon: a single centre experience. European journal of haematology. 2010 Feb 1:84(2):97-104. doi: 10.1111/j.1600-0609.2009.01370.x. Epub 2009 Nov 3
[PubMed PMID: 19889011]
[14]
Jiang RS, Zhao ZY. Multimodal treatment of Kasabach-Merritt syndrome arising from tufted angioma: A case report. Oncology letters. 2017 Jun:13(6):4887-4891. doi: 10.3892/ol.2017.6064. Epub 2017 Apr 20
[PubMed PMID: 28599491]
Level 3 (low-level) evidence
[15]
Croteau SE, Gupta D. The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. Seminars in cutaneous medicine and surgery. 2016 Sep:35(3):147-52. doi: 10.12788/j.sder.2016.048. Epub
[PubMed PMID: 27607323]
[16]
Drolet BA, Trenor CC 3rd, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. The Journal of pediatrics. 2013 Jul:163(1):285-91. doi: 10.1016/j.jpeds.2013.03.080. Epub
[PubMed PMID: 23796341]
Level 3 (low-level) evidence
[17]
Zhou SY, Li HB, Mao YM, Liu PY, Zhang J. Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids. Journal of pediatric surgery. 2013 Mar:48(3):673-6. doi: 10.1016/j.jpedsurg.2012.12.049. Epub
[PubMed PMID: 23480932]
[18]
Wang Z, Li K, Dong K, Xiao X, Zheng S. Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work. The Journal of dermatology. 2015 Apr:42(4):401-4. doi: 10.1111/1346-8138.12797. Epub 2015 Feb 24
[PubMed PMID: 25728547]
[19]
Wang H, Duan Y, Gao Y, Guo X. Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients. Pediatric dermatology. 2017 May:34(3):261-265. doi: 10.1111/pde.13077. Epub 2017 Feb 15
[PubMed PMID: 28198567]